Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B
Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in its investigational stem cell therapy, Lomecel-B. The ... Read More
CHMP backs Lecanemab again for early Alzheimer’s as EC reviews approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has reaffirmed its positive opinion on lecanemab, a monoclonal antibody therapy developed by ... Read More
C2N Diagnostics bags UK MHRA approval for PrecivityAD2 blood test, advancing Alzheimer’s diagnosis
C2N Diagnostics, LLC, a leader in advanced diagnostic solutions for neurodegenerative diseases, has obtained medical device certification from the United Kingdom’s Medicines and Healthcare products ... Read More
Neuphoria Therapeutics secures milestone payment from Merck as Alzheimer’s clinical trial advances
Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a late-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, has announced that it will receive a $15 million ... Read More
Mental stimulation may reduce Alzheimer’s risk, study suggests
As people age, it is common to experience subtle changes in memory and cognitive function. Forgetting familiar names, struggling to recall recent events, or having ... Read More
C2N’s PrecivityAD2 blood test improves Alzheimer’s diagnosis and clinical decision-making, study finds
A new study has demonstrated that healthcare providers who used the PrecivityAD2 blood biomarker test, developed by C2N Diagnostics, significantly improved their ability to assess ... Read More
FDA approves Leqembi maintenance dosing for early Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi (lecanemab-irmb), an innovative treatment for early Alzheimer’s disease developed ... Read More
InMed Pharmaceuticals’ INM-901 shows breakthrough potential in Alzheimer’s disease treatment
In a significant development in Alzheimer’s disease research, InMed Pharmaceuticals Inc., a biotechnology company specialising in the development of proprietary small molecule drug candidates, announced ... Read More
Firefly Neuroscience’s BNA platform unlocks early Alzheimer’s screening potential
Firefly Neuroscience, Inc., a prominent artificial intelligence company focused on brain health innovation, has announced a groundbreaking advancement in the measurement of brain age using ... Read More
Actinogen Medical progresses in XanaMIA Phase 2b/3 trial for Alzheimer’s disease
Actinogen Medical Limited (ASX: ACW) has announced a major milestone in its ongoing XanaMIA Phase 2b/3 clinical trial, aimed at treating biomarker-positive mild to moderate ... Read More